GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermira Inc (NAS:DERM) » Definitions » Net Current Asset Value

Dermira (Dermira) Net Current Asset Value : $-0.17 (As of Sep. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Dermira Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Dermira's net current asset value per share for the quarter that ended in Sep. 2019 was $-0.17.

The historical rank and industry rank for Dermira's Net Current Asset Value or its related term are showing as below:

DERM's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.96
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Dermira Net Current Asset Value Historical Data

The historical data trend for Dermira's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermira Net Current Asset Value Chart

Dermira Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Net Current Asset Value
Get a 7-Day Free Trial 3.28 6.03 6.14 3.48 -0.42

Dermira Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 -0.42 1.04 0.86 -0.17

Competitive Comparison of Dermira's Net Current Asset Value

For the Biotechnology subindustry, Dermira's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermira's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermira's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Dermira's Price-to-Net-Current-Asset-Value falls into.



Dermira Net Current Asset Value Calculation

Dermira's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2018 is calculated as

Net Current Asset Value Per Share(A: Dec. 2018 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(335.409-353.36-0-0)/42.3282
=-0.42

Dermira's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2019 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2019 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(412.519-421.761-0-0)/54.5212
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermira  (NAS:DERM) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Dermira Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Dermira's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermira (Dermira) Business Description

Traded in Other Exchanges
N/A
Address
275 Middlefield Road, Suite 150, Menlo Park, CA, USA, 94025
Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.
Executives
Halley E Gilbert director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
William R Ringo director
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
David E Cohen director 3160 PORTER DRIVE, PALO ALTO CA 94304
Thomas G Wiggans director, officer: CEO & Chairman of the Board
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Andrew Guggenhime officer: CFO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Lori Lyons-williams officer: Chief Commercial Officer C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Kathleen Sebelius director C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Eugene A Bauer director, officer: Chief Medical Officer C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Mark Mcdade director C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Canaan Partners Viii Llc director 285 RIVERSIDE AVE, STE 250, WESTPORT CT 06880
Canaan Viii Lp director 2765 SAND HILL RD, MENLO PARK CA 94025

Dermira (Dermira) Headlines

From GuruFocus

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

By Stock market mentor Stock market mentor 01-20-2023